Differential expression of the closely linked KISS1, REN, and FLJ10761 genes in transgenic mice.
THE REN GENE EXHIBITS an exquisitely restricted temporal and spatial profile of expression in mammals (28) . The main site of renin synthesis leading to circulating protein is the kidney where its expression is limited to a few epithelioid cells at the distal end of the afferent arteriole proximal to the glomerulus. These juxtaglomerular cells make up less than 0.1% of the cellular mass of the kidney and have the ability to regulate REN transcription, synthesis, and processing over a two-order of magnitude range depending on the physiological status of the organism (6) . The pattern of expression and the transcriptional responses to physiological cues is strongly conserved in mammals. Mechanisms must therefore exist to faithfully control the temporal and spatial expression of this important gene.
To examine the mechanisms regulating expression of REN, we previously generated a transgenic mouse model containing a 160-kb P1 artificial chromosome (PAC160) (29, 30) . This large clone contains the REN gene and ϳ75 kb and 70 kb of 5Ј and 3Ј flanking sequence, respectively. Expression of REN is restricted to the kidney, but in mice containing a high number of transgene copies, expression is also evident in the brain, lung, and placenta (17) . In the kidney, the REN transgene is only expressed in juxtaglomerular cells, and its synthesis is highly regulated in response to cues that normally upregulate (ACE inhibition, low-sodium diet) or repress (high-sodium diet, pressor and subpressor infusion of ANG II) expression of the gene. Double transgenic mice containing PAC160 and a systemically expressed human angiotensinogen (hAGT) gene exhibit a 20 mmHg increase in systemic arterial pressure, which is much lower than double transgenic mice expressing a poorly regulated human REN transgene (29) . Indeed, human REN expression in the kidney is strongly suppressed in the PAC160/hAGT double transgenic mice. All the current data suggest that the PAC160 transgenic mouse is the most faithfully accurate model for studying the regulation of human REN expression generated to date.
One of the most interesting findings from the PAC160 mouse model is that expression of REN is proportional to transgene copy number and immune from position effects on expression. This rarely occurs when small transgenes containing cDNAs are expressed in mice. Copy number proportional expression generally indicates an ability to organize chromatin at the local level (7, 11) . This insulates the transgene from effects caused by integration near other strong regulatory elements controlling genes located at or near the site of insertion. The formation of a "minilocus" of expression may be due to the presence of dominant control regions or nuclear matrix attachment sites in the transgene. Although such elements have yet to be mapped near REN, a strong enhancer of transcription located 12 kb upstream of the gene has been identified and partially characterized (25) (26) (27) 37) . This enhancer was identified on the basis of homology to a similar sequence 2.6 kb upstream of the mouse renin gene which can strongly transactivate the gene in renin-expressing cells (22) . It remains unclear whether this enhancer has properties similar to dominant control regions.
In this study we asked whether other genes are present on the PAC160 transgene, whether they are expressed in PAC160 transgenic mice, and whether their expression pattern is similar or dissimilar to REN. We demonstrate that PAC160 contains complete copies of the tumor suppressor gene KISS1 and the hypothetical gene encoding a ethanolamine (choline) kinaselike enzyme FLJ10761. These genes exhibit a distinct but partially overlapping pattern of tissue-specific expression in PAC160 mice that emulates their expression in human tissues. water ad libitum unless specified. Placental samples were obtained after killing pregnant mice when they were close to full term. Care of the mice used in the experiments met the standards set forth by the National Institutes of Health in their Guidelines for the Care and Use of Laboratory Animals, and all procedures were approved by the University Animal Care and Use Committee at the University of Iowa.
Analysis of nucleic acids. Total RNA was prepared using either the guanidium thiocyanate (GITC) or the Tri-Reagent protocol as described previously (29) . Northern blot analysis was performed according to standard protocols using 15 g of total RNA isolated from each tissue. The presence of intact ribosomal RNA bands and equality of loading between lanes was checked by staining with methylene blue. Custom-made Northern blots were obtained from Clontech (Palo Alto, CA). Each lane had 1 g of poly(A) ϩ RNA, which was normalized, based on the signal for a housekeeping gene. Prehybridization and hybridization was carried out according to the manufacturer's instructions.
RT-PCR was performed to generate FLJ10761 and KISS1 using the following primers: FLJRT-UP (GAATGAGGTCAGAAACTTC-CAG), FLJRT-DN (TCTTGTGCCAGAGGATGGGCTTG), KISS1-UP (AATTCTAGACCCACAGGCCA), and KISS1-DN (GCATGCTCTG-ACTCCTTTGGG). RT-PCR bands were gel purified (Wizard Promega kit) and ligated into pCR2.1 using protocols from the manufacturer (Invitrogen). The renin cDNA probe was described previously (29) . The cloned PCR products were used as probes on Northern blots.
RNase protection assays (RPAs) were performed using a commercially available kit (Ambion, Austin, TX). Total RNA of 20 g was hybridized with 2 ϫ 10 4 dpm of FLJ10761 and REN probe and 1 ϫ 10 4 dpm of 28S probe. RNase digestion was performed with a mixture of RNase A (250 U/ml) and RNase T1(10,000 U/ml) at a dilution of 1:100. The rest of the protocol was followed as specified by the manufacturer. Probe templates for RPAs were obtained from RT-PCR reactions. The FLJ10761 probe was cloned into pCR2.1 as described above. This plasmid was linearized at the 5Ј end using Spe1 to generate a template for an RPA probe. The template for renin was generated by linearization with BamHI of a plasmid containing renin cDNA.
Databases. Maps and sequences were obtained from the Ensembl database at the Sanger Centre (http://www.sanger.ac.uk/), the human Map Viewer from the National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/mapview/static/ MVstart.html), and the Human Genome Browser Gateway at University of California Santa Cruz (UCSC; http://genome.ucsc.edu/cgibin/hgGateway). Homology searches were performed using the BLAST program of NCBI and Ensembl, and the relative position of genes on PAC160 was confirmed by BLAT analysis. Sequence tagged site (STS) marker information was obtained from a combination of NCBI and Ensembl (D1S2480, D1S1725, D1S2717, D1S2668, D1S387, and D1S510) databases. Primers were obtained from Genosys (Sigma-Genosys Biotechnologies). Sequencing was performed at the DNA core facility at the University of Iowa. Sequencing results were analyzed using DNASTAR software package. Sequence analysis of the PAC ends was performed using purified PAC DNA and the SP6 and T7 primers.
RESULTS
REN is centered on PAC160 ϳ75 kb from the SP6 end (left end of Fig. 1 ) and 70 kb from the T7 end (right end of Fig. 1 ). At the inception of this project, only a cursory sequence of unordered fragments was available for this section of human chromosome 1. Originally therefore, we verified the presence of KISS1 and FLJ10761 on PAC160 by PCR amplification of several exons from each gene and mapped the position of several linked STS using purified PAC160 DNA as the template (data not shown). The order of the genes and their relative spacing was verified with the completed draft of the human genome sequence and was confirmed in the latest freeze (July 2003). The completed sequence also revealed the presence of 2 . Expression of the REN gene. Tissue-specific expression of the REN gene in humans (top) and PAC160 mice (bottom) is shown. B, brain; H, heart; Sk, skeletal muscle; C, colon; Ty, thymus; Sp, spleen; K, kidney; Lv, liver; I, intestine; Pl, placenta; Lg, lung; PBL, peripheral blood lymphocytes; Sg, salivary gland; Pa, pancreas; KϪ, kidney from nontransgenic littermate. PEPP3 and SOX13 as flanking genes (Fig. 1) . Sequence analysis of the ends of the PAC160 insert revealed that both PEPP3 and SOX13 are incomplete. Only the terminal 6 (of 23) exons of PEPP3 are present, whereas all of SOX13 is present except the 5Ј flanking region and exon 1. As expected therefore, neither gene is expressed in transgenic mice containing PAC160 (data not shown).
Examination of the mouse chromosome 1 sequence (October 2003 freeze) confirmed the gene order Pepp3-Kiss1-Ren1 cSox13. Listed in the database between mouse Ren1 c and Sox13 is an expressed sequence tag (EST; RIKEN cDNA, NM_175443) that has 67% overall identity and 85% identity within the 5Ј-most sequence with human FLJ10761, suggesting synteny in this region of human and mouse chromosome 1. Detailed analysis of the sequence of a BAC clone encoding the Ren locus from the 129/SvEv mouse strain (accession no. AC024068) further confirms that the gene order Pepp3, Kiss1, Ren, Flj10761, and Sox13 is highly conserved. Interestingly, the 129/SvEv strain, like several other strains, contains a duplication at the Ren locus and encodes two Ren genes, Ren2 
Given the close proximity between KISS1, REN, and FLJ10761, in particular REN and FLJ10761, we asked whether they exhibited similar or disparate tissue-specific expression profiles and whether that pattern would be retained in transgenic mice containing multiple copies of PAC160. Expression of REN, KISS1, and FLJ10761 was first examined in human tissues using Clontech's preprepared multiple tissue Northern blots and then in tissues from PAC160 transgenic mice. FLJ10761 expression was confirmed in four different transgenic lines, whereas KISS1 was confirmed in two of these transgenic lines.
As anticipated, expression of REN was abundant in human kidney and was detectable in placenta (Fig. 2) . In PAC160 mice, REN was abundantly expressed in kidney and placenta and, in the transgenic mice shown here containing a high number of transgene copies, also in brain and lung. Expression of REN in the brain and lung has been previously reported by us and others (14, 31, 35) .
Interestingly, despite the observation that FLJ10761 lies only a few kilobases downstream of REN, it exhibits a distinct tissue-specific expression profile with abundant expression in the liver, kidney, and testes, and moderate expression in pancreas, ovary, and prostate (Fig. 3) . The pattern of FLJ10761 expression in four lines of transgenic mice was remarkably similar to the pattern detected in human tissue with high-level expression evident in liver, kidney, and testes (Fig. 4) . Some differences in relative abundance of FLJ10761 mRNA was detected among tissues from different lines (i.e., relative abundance in liver and kidney in lines 7217/2 and 6919/1).
On the contrary, KISS1 expression in humans was only abundantly detected in placenta, with much lower levels evident in heart, liver, skeletal muscle, and spleen (Fig. 5) . Although in much smaller abundance than placenta, the transcripts detected in skeletal muscle and testes appear larger than the placental transcript, whereas a much smaller transcript was detected in heart, liver, and kidney. In transgenic mice, expression was evident in the kidney, brain, and lung, a finding reproduced in two different transgenic lines (Fig. 6 ). There was no detectable endogenous Kiss1 mRNA in these samples. Expression of KISS1 was also evident in placenta from PAC160 mice, but at a much lower level than anticipated (Fig.  7) . The low signal in the nontransgenic placenta samples most likely reflects expression of the endogenous mouse Kiss1 gene, which is 85% identical to human KISS1.
Given the copy number proportional expression of REN in PAC160 mice previously reported by us (29), we determined whether expression of FLJ10761 would be similarly proportional to copy number. Expression of REN and FLJ10761 was examined in kidney and liver from five different lines classified as having low (L), medium (M), or high (H) copy number of the PAC transgene (Fig. 8) . Although expression of 28S rRNA was constant in all samples, expression of both REN and FLJ10761 was stronger in mice containing the medium and high number of copies than in mice containing only 1-2 copies of PAC160. Copy number proportional expression of FLJ10761 was evident in both kidney and liver, whereas REN expression was only evident in kidney.
DISCUSSION
The precision by which a transgenic animal model closely emulates a physiological or pathophysiological process depends largely upon the quality and quantity of transgene expression. Important questions to be asked in any transgenic experiment include: Is the transgene expressed in the correct spectrum of cells and tissues? Is the level of expression physiological or pharmacological? Whereas intronic sequences are known to be important for the overall processing and level of transgene expression (3), ultimately, it is the promoter and regulatory sequences which govern the pattern of temporal and spatial expression observed in the animal. Transgenes consisting of promoters lacking important regulatory elements can exhibit ectopic and variegated expression, and few transgenes exhibit copy number proportional expression (reviewed in Ref. 16 ). We show herein that a large transgene consisting of the REN locus and surrounding loci from human chromosome 1 exhibits copy number proportional expression of REN and the next downstream gene FLJ10761.
Copy number proportional expression of transgenes in mice is the exception not the rule. Copy number proportional expression is most prevalent in mice which contain large transgenes consisting of genomic DNA (exons and introns) and sequences having the ability to manipulate chromatin locally (11, 33) . Grosveld and colleagues (10) described a series of DNase I hypersensitive sites in genomic DNA surrounding the ␤-globin locus which constitute a dominant (or locus) control region (DCR or LCR). Core sequences containing the DNase hypersensitive sites can confer copy number proportional expression in transgenic mice (34) . Given the copy number proportional expression observed in mice containing PAC160, it becomes attractive to hypothesize that an LCR may exist near the REN locus. That expression of FLJ10761 was also proportional to copy number begs the question of whether a single LCR or multiple LCRs are present in PAC160.
What is the nature of the renin LCR? The ␤-globin LCR consists of a series of hypersensitive sites and binding sites for both ubiquitous and erythroid cell-specific transcription factors (34) . The renin enhancer, first identified by Gross and colleagues (22) , is located about 2.6 kb upstream of the mouse renin gene. A homologous sequence is located about 12 kb upstream of the human renin gene (KE in Fig. 1) (25, 37) . This sequence contains the binding sites for at least 10 different transcription factors including NF-Y, RAR␣, RXR␣, CREM, CREB, USF-1, USF-2, Ear2, Sp1, and Sp3 (15, 20, 21, (25) (26) (27) . By analogy with ␤-globin, it is possible that the renin enhancer acts as an LCR. Using homologous recombination in bacteria to subtly alter PAC160 (19), we have generated a new transgene (PAC160⌬KE) identical in all respects except it lacks the Fig. 7 . Expression of the KISS1 gene in placenta from PAC160 mice. Tissue-specific expression of the KISS1 gene in placenta of PAC160 mice is shown. Placentas were obtained from late-term pregnancies and were genotyped to determine whether these carried the PAC160 transgene (ϩ) or not (Ϫ). Control RNA was from human placenta. kidney enhancer. We are currently examining the expression and regulation of REN, FLJ10761, and KISS1 in mice containing the altered construct to assess its importance as an LCR.
Expression of FLJ10761 in PAC160 mice closely emulated its normal pattern of expression in humans, that is, high-level expression in the kidney, liver, and testes. It is intriguing that FLJ10761 is located only 3.7 kb downstream of renin yet exhibits high-level expression in the liver where renin is not expressed. A similar situation was reported for the chicken lysozyme (cLys) locus. Just 207 bp downstream of cLys is the cGas41 gene, which exhibits a vastly different expression pattern than cLys (4). Interestingly, cLys and cGas41 are separated by a CpG island, which is commonly associated with 1) the promoters of housekeeping genes (8) and 2) origins of replication (2) . Interestingly, a NotI restriction site, which is rich in CpG dinucleotides (GCGGCCGC) and present in some CpG islands, is located in the first intron of FLJ10761 (Fig. 1) . Moreover, the UCSC Human Genome Browser places a CpG island around the transcription start site for FLJ10761 (Fig. 1) , suggesting the presence of a "natural expression boundary" between REN and FLJ10761. Nevertheless, recall that both REN and FLJ10761 share copy number proportional expression, suggesting that other sequences may be present in PAC160 that act as a chromatin organizer.
Further analysis of 1 kb of sequence upstream of FLJ10761 exon 1 with TRANSFAC revealed a number of potentially interesting transcription factor binding sites including MTF-1 (metal element protein-1), which is active in liver, kidney, and testes (just as FLJ10761), and ANF-2, which is reported to be liver specific (36) . The most interesting finding was the identification of a fully consensus binding site for LF-A1 ϳ85 bp upstream of the transcription start site. This site is present in several liver-specific genes including ␣1-antitrypsin, pyruvate kinase, and apolipoproteins A1, B1, and A4 (23) . Additional studies will be needed to clarify the importance of this site in liver-specific expression of FLJ10761.
There is scant information on the functional relevance of FLJ10761. The Swiss-Prot database lists it as a hypothetical protein potentially encoding a choline-or ethanolamine-kinase (EKI2). EKI proteins normally catalyze the first step in phosphatidylethanolamine biosynthesis, an abundant phospholipid in cell membranes. It is evolutionarily conserved with homologs in mouse, zebrafish, worms, and yeast. Knockdown of EKI homologs in worms using RNA interference does not result in any observed phenotype (from WormBase database, http://www.wormbase.org/).
On the contrary, substantial information continues to emerge on the function of KISS1. KISS1 is a metastasis suppressor gene which inhibits metastasis in a number of experimental model systems (reviewed in Ref. 12) . A COOH-terminal peptide derived from KISS1, termed metastin, released into the circulation from the placenta during pregnancy, is thought to mediate the biological effects of KISS1 (13) . Recently, a G-protein-coupled receptor has been identified as the receptor for metastin (32) . This pathway may play a role in the gonadotropic axis, as loss of function mutations of the metastin receptor can cause hypogonadotropic hypogonadism (5). A similar phenotype was observed in knockout mice lacking the receptor (24).
KISS1 is abundantly expressed in the placenta and has been reported in brain (18) . In PAC160 mice, KISS1 was abundantly expressed in lung with lower levels in brain and kidney. Although its expression in brain is consistent with other reports, its expression in kidney and lung cannot be easily reconciled. Moreover, KISS1 expression in the placenta of PAC160 transgenic fetuses was also substantially lower than anticipated. It is possible that since the pattern of KISS1 expression in PAC160 mice was similar to the expression of REN, the KISS1 promoter may have been influenced by sequences regulating REN. Recall, placental KISS1 was detected in lines of PAC160 mice containing multiple copies of the transgene. Along similar lines, a second transcriptional enhancer termed the chorionic enhancer (CE in Fig. 1 ) has been reported ϳ5 kb upstream of human REN (9) . This enhancer is capable of strongly trans-activating the human REN promoter in primary chorionic cells, but less strongly in renin-expressing cells derived from the kidney and lung. It becomes tempting to speculate that the chorionic enhancer may have dual actions as a REN and KISS1 enhancer. As above, we are directly testing this in transgenic mice containing a modified PAC160 transgene lacking the chorionic enhancer (PAC160⌬CE).
In conclusion, transgenic mice containing large chromosomal segments can be excellent tools with which to study the coordinate expression and regulation of closely linked genes in an experimental context where the human expression pattern is retained. Mutational studies provide further opportunities to identify regulatory elements that act in a gene-specific or locus-specific manner.
